Five-Year OS Data for Dabrafenib/Trametinib Combo in Melanoma

Video

Georgina V. Long, BSc, PhD, MBBS,&nbsp;professor of medical melanoma oncology, Melanoma Institute Australia, discusses 5-year overall survival data from a phase II trial of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with <em>BRAF V600</em>-mutant unresectable or metastatic melanoma during the 2017 ASCO Annual Meeting.

Georgina V. Long, BSc, PhD, MBBS, professor of medical melanoma oncology, Melanoma Institute Australia, discusses 5-year overall survival data from a phase II trial of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients withBRAF V600

Recent Videos
Related Content
Real-World CAR T-Cell Therapy Outcomes in DLBCL Reveal Challenges and Disparities

Real-World CAR T-Cell Therapy Outcomes in DLBCL Reveal Challenges and Disparities

Kristie L. Kahl
November 15th 2024
Article

Read More

Advancing Melanoma Treatment: Hamid on Lifileucel's Role

Advancing Melanoma Treatment: Hamid on Lifileucel's Role

Jordyn Sava;Omid Hamid, MD
July 15th 2024
Podcast

In this episode of Targeted Talks, Omid Hamid, MD, discusses data supporting the use of lifileucel for the treatment of advanced melanoma.

Listen

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Advancements in Follicular Lymphoma Treatment With Targeted Therapies

Morgan Bayer
November 14th 2024
Article

At the 42nd Annual Chemotherapy Foundation Symposium, Erin Mulvey, MD, discussed the significant progress being made in the treatment of relapsed or refractory follicular lymphoma.

Read More

Understanding and Treating Mucosal Melanoma

Understanding and Treating Mucosal Melanoma

Nichole Tucker;Richard Carvajal, MD
April 14th 2023
Podcast

In season 4, episode 4 of Targeted Talks, Richard D. Carvajal, MD, discusses mucosal melanoma and treatment options for the disease.

Listen

Bringing Bispecific Antibody Therapy to Community Oncology Centers

Bringing Bispecific Antibody Therapy to Community Oncology Centers

Jordyn Sava
October 11th 2024
Article

In an interview with Targeted Oncology, Courtney Van Houzen, PharmD, shared her experience in bringing bispecific antibody treatments to a community setting.

Read More

Long-Term Success With Anti–LAG-3/Anti–PD-1 Combo in Metastatic Melanoma

Long-Term Success With Anti–LAG-3/Anti–PD-1 Combo in Metastatic Melanoma

Sabrina Serani
October 11th 2024
Article

Meredith McKean, MD, MPH, discussed findings from a longer-term follow-up study evaluating fianlimab plus cemiplimab for the treatment of metastatic melanoma.

Read More